Latest Articles

Publication Date
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer - The AI Journal

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer The AI Journal

Published: Dec. 22, 2025, 7:31 a.m.
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer - itemonline.com

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer itemonline.com

Published: Dec. 22, 2025, 7:30 a.m.
Adjuvant Chemoradiotherapy Provides Long-Term Survival Benefits in High-Risk Endometrial Cancer - OncLive

Adjuvant Chemoradiotherapy Provides Long-Term Survival Benefits in High-Risk Endometrial Cancer OncLive

Published: Dec. 22, 2025, 5:26 a.m.
New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial - geneonline.com

New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial geneonline.com

Published: Dec. 21, 2025, 12:34 p.m.
Brian Slomovitz: New Study on PARP Therapy Advances in Endometrial Cancer - Oncodaily

Brian Slomovitz: New Study on PARP Therapy Advances in Endometrial Cancer Oncodaily

Published: Dec. 19, 2025, 7:56 p.m.
Endometriosis as an immune-mediated disease: pathogenetic mechanisms and therapeutic strategies.

Endometriosis, which affects approximately 10% of women of reproductive age, is a complex inflammatory disease with significant immune system disturbances caused by an inadequate immune response to retrograde menstruation and …

Published: Dec. 18, 2025, midnight
Immunotherapy in Endometrial Cancer: Mechanisms, Clinical Evidence, and Future Directions - Frontiers

Immunotherapy in Endometrial Cancer: Mechanisms, Clinical Evidence, and Future Directions Frontiers

Published: Dec. 17, 2025, 5:24 p.m.
Ovarian squamous cell carcinoma: clinicopathological features, prognosis and immunotherapy outcomes.

To explore the characteristics and survival outcomes of ovarian squamous cell carcinoma (SCC) and the treatment effectiveness of immune checkpoint inhibitors (ICIs).

Published: Dec. 17, 2025, midnight
Borderline ovarian clear cell tumor arising from endometriosis during long-term dienogest therapy: a case report.

Endometriomas, commonly known as ovarian chocolate cysts, are a prevalent condition in women of reproductive age. They are cysts formed by the ectopic growth of endometrial tissue within the ovary, …

Published: Dec. 17, 2025, midnight
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Therapy for Advanced Endometrial Cancer - Cancer Nursing Today

Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next Therapy for Advanced Endometrial Cancer Cancer Nursing Today

Published: Dec. 15, 2025, 8:24 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!